Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01513044 | Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fasting Conditions | PHASE1 | COMPLETED | 68 | — | — | Jan 1, 2009 | Jan 1, 2009 | Jan 20, 2012 | 1 | India |
| NCT01513057 | Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions | PHASE1 | COMPLETED | 61 | — | — | Jan 1, 2009 | Feb 1, 2009 | Jan 20, 2012 | 1 | India |
| Arm | Type | Description |
|---|---|---|
| Mycophenolate Mofetil | EXPERIMENTAL | Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited |
| Cellcept | ACTIVE_COMPARATOR | Cellcept 250 mg capsules of Roche Laboratories Inc. |
| Name | Type | Description |
|---|---|---|
| Mycophenolate Mofetil | DRUG | Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited |
Inclusion Criteria: * Subjects aged between 18 and 50 years (including both). * Subjects' weight within the normal range according to normal values for the Body * Mass Index (1 8.5 to 24.9 kg/m2) with minimum of 50 kg weight. * Subjects with clinically acceptable normal health as determined by pers...